Journal of Medicinal Chemistry p. 11301 - 11323 (2019)
Update date:2022-08-17
Topics:
Lu, Yunlong
Gutgesell, Lauren M.
Xiong, Rui
Zhao, Jiong
Li, Yangfeng
Rosales, Carlo I.
Hollas, Michael
Shen, Zhengnan
Gordon-Blake, Jesse
Dye, Katherine
Wang, Yueting
Lee, Sue
Chen, Hu
He, Donghong
Dubrovyskyii, Oleksii
Zhao, Huiping
Huang, Fei
Lasek, Amy W.
Tonetti, Debra A.
Thatcher, Gregory R. J.
The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials. These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood-brain barrier penetration. A novel family of benzothiophene SERDs with a basic amino side arm (B-SERDs) was synthesized. Proteasomal degradation of ERα was induced by B-SERDs that achieved the objectives of oral and brain bioavailability, while maintaining high affinity binding to ERα and both potency and efficacy comparable to fulvestrant in cell lines resistant to endocrine therapy or bearing ESR1 mutations. A novel 3-oxyazetidine side chain was designed, leading to 37d, a B-SERD that caused endocrine-resistant ER+ tumors to regress in a mouse orthotopic xenograft model.
View MoreContact:86-0510-85133006
Address:hubin road NO157
Zhushan County Tianxin Pharmaceutical & Chemical Co., Ltd.
Contact:0086-719-4224892
Address:Tutang Road, Chengguan Town, Zhushan County, Hubei Province
Sichuan Sangao Biochemical Co., Ltd
Contact:+86-28-84874233
Address:19F, Bldg.2, Shudu Center, Tianfu 2nd St., Hi-tech zone, Chengdu 610041, Sichuan Province, China.
Xinchang Yueding Chemical Co., Ltd.
Contact:86-571-56926323
Address:NO.90 BEIMENCHENGWAI CHENGGUAN TOWN XINCHANG
Contact:13357117572
Address:No.149 Shiji dadao Road.
Doi:10.1134/S1070427219060119
(2019)Doi:10.1246/bcsj.50.2272
(1977)Doi:10.1021/ja0497025
(2004)Doi:10.1021/jo0255429
(2002)Doi:10.1016/S0040-4039(00)80281-6
(1988)Doi:10.1021/om061133h
(2007)